DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 021986/S-016
NDA 021986/S-017

SUPPLEMENT APPROVAL
FULFILLMENT OF POSTMARKETING REQUIREMENT

Bristol-Myers Squibb
Attention: Kruti Patel, RPh
Associate Director, Global Regulatory Sciences
P.O. Box 4000
Princeton, NJ 08543

Dear Ms. Patel:

Please refer to your Supplemental New Drug Applications (sNDA) dated October 14, 2014 and February 12, 2015 received October 14, 2014 and February 12, 2015, respectively, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Sprycel® (dasatinib) 20, 50, 70, 80, 100 and 140 mg tablets.

We also refer to our approval letter dated August 12, 2015, which contained the following error: an inaccurate description of S-016.

This replacement approval letter incorporates the correction of the error. The effective approval date will remain August 12, 2015, the date of the original approval letter.

We acknowledge receipt of your amendments dated November 10, 2014; January 12, 20, 28; February 2 and 12; March 27; April 1; June 16; July 15 and 30; and August 11 and 12, 2015.

This "Prior Approval" supplemental new drug application (S-016) provides for regular approval for the treatment of adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, and the inclusion of data from trial CA180056 entitled "An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib versus Standard Dose Imatinib in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia".

"Prior Approval" supplemental new drug application (S-017) provides for new Warnings and Precautions subsection for "Severe Dermatological Reactions", the Adverse Reactions – Post Marketing Experience section was revised to include Stevens Johnson Syndrome (SJS). In addition, the pregnancy-related sections of the label were updated.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

We are waiving the requirements of 21 CFR 201.57(d) (8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and the text for the patient package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l) (1) (i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

SUBPART H FULFILLED

We approved this NDA under the regulations at 21 CFR 314 Subpart H for accelerated approval of new drugs for serious or life-threatening illnesses. Approval of this supplement fulfills your commitment made under 21 CFR 314.510.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

FULFILLMENT OF POSTMARKETING REQUIREMENT

We refer to your supplemental New Drug Application (sNDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Sprycel (dasatinib) 20, 50, 70, 80, 100 and 140 mg tablets.

We have received your submission dated October 14, 2014, containing the final report for the following postmarketing requirement listed in the October 28, 2010 approval letter.

PMR 1699-1 To submit the final report (at least 60 months of follow-up) and data from CA180056 entitled, "An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib versus Standard Dose Imatinib in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia."

The timetable you submitted on October 21, 2010, states that you will conduct this trial according to the following schedule:

Protocol Submission:	by September 2009
Trial Completion:	by February 2014
Final Report and Dataset Submission:	by November 2014

We have reviewed your submission and conclude that the above requirement was fulfilled.

This completes all of your postmarketing requirements and postmarketing commitments acknowledged in our October 28, 2010 letter.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b) (3) (i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a) (4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a) (4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Janet G. Higgins, Regulatory Project Manager, at (240) 402-0330.

Sincerely,

{See appended electronic signature page}

Edvardas Kaminskas, M.D.
Deputy Director
Division of Hematology Products
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

EDVARDAS KAMINSKAS
08/12/2015